Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…re recorded. At the end of follow-up, two patients continued on risankizumab monotherapy, while three maintained the combination therapy.Con…
…everity, and management of irAEs in melanoma patients receiving ipilimumab–nivolumab therapy.Material and Methods A retrospective observat…
…erval (33.3%) and to restart the drug (25.0%). In patients with ustekinumab, the main interventions were to shorten the dosing interval (55…
…ents received upadacitinib(47.7%), 15 tofacitinib(34.1%), and 8 filgotinib(18.2%). Thirteen patients (29,5%) received concomitant treatmen…
…er during flares. Three novel TNFAIP3 variants were identified. Colchicine was effective as monotherapy in 40%. TNF-inhibitors showed the …
…y initiated systemic corticosteroids, mycophenolate mofetil and infliximab, resulting in partial disease control. This case highlights a u…
…ment with seton placement and concomitant anti-TNF (infliximab, adalimumab) allows wound healing in 40%–70% of cases. The currently availa…
…re, limiting its utility. Janus kinase inhibitors, particularly upadacitinib, have shown promise in observational studies, but data remain l…
…up of disorders characterised by acute or chronic inflammation. Adalimumab and infliximab are the cornerstones of their pharmacotherapy. T…
…present a case of a woman in her early 30s who was commenced on certolizumab, another TNF-α inhibitor, for the management of her psoriasis, …
…ne with antiepileptics and anticoagulants. She was initiated on infliximab during the rehabilitation phase. The primary disease is under p…
…hn’s disease were followed-up after initiation of infliximab or adalimumab. A frailty index (FI) was constructed using variables collected…